Answers are grounded in this paper and cite their sources.
Demonstrates improved drug delivery and reduced dosing frequency in diabetes management, suggesting enhanced patient compliance.
Background: Diabetes mellitus is a long-term illness that needs sustained therapy to keep glycemic control intact. Glipizide is an effective second-generation sulfonylurea but has a short half-life, thus requiring prolonged dosing that compromises compliance in patients. Controlled-release drug delivery systems provide an answer by delivering constant drug levels over a long duration of time. Osmotic controlled-release tablets, specifically, facilitate drug delivery irrespective of gastrointestinal motility and pH, which makes them suitable for drugs such as Glipizide. Objective: Innovative drug delivery systems have advanced oral controlled-release systems, offering benefits over immediate-release forms by maintaining consistent drug concentration, reducing dosing frequency, and improving patient adherence. Methods: Tablet cores were prepared via wet granulation and coated with cellulose acetate and potassium chloride for semipermeable membranes. Pre-compression parameters of the granules indicated excellent flow properties, while post-compression parameters such as weight variation, hardness, friability, and drug content met the required standards. In-vitro dissolution studies revealed variable drug release profiles among different formulations, attributed to the choice and concentration of osmotic agents. The F-02 formulation, containing Mannitol and Fructose, demonstrated extended drug release over 12 hours. Results- in the Kinetic analysis of drug release indicated that most formulations followed zero-order kinetics, with an Anomalous non-Fickian diffusion mechanism. This suggests that the release of Glipizide from OCR tablets is not solely governed by Fickian diffusion but is also influenced by other mechanisms. Conclusion: The development of Glipizide OCR tablets offers a promising approach to improve drug delivery, reduce dosing frequency, and enhance patient compliance in treating diabetes.
No takes yet. Share an insight, caveat, or question.
Waghamare et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: